<p>The two buyout firms that own Pharmaceutical Product Development (PPD) are in advanced talks to sell minority stakes in the US clinical trials firm to investors that include Singapore's sovereign wealth fund GIC and Abu Dhabi Investment Authority.</p>
<p>The sale would be at a price that would value the entire company at more than US$9 billion (S$12.58 billion), including debt, people familiar with the matter said.</p>